09-24 AGC Biologics Provides Process Development, Scale-Up, And GMP Manufacturing Services For Flen Health CI
01-26 Autolus Limited Enters into Master Service Agreement with AGC Biologics S.P.A CI
01/08/25 Genenta Science S.p.A. Notifies AGC Biologics S.p.A. of its Intent to Terminate Work Statement No. 01 CI
31/07/25 European Commission Approves CAR-T Therapy with Lentiviral Vectors Manufactured by AGC Biologics CI
30/12/24 Genenta Science S.p.A. and AGC Biologics S.p.A. Enters into the Second Amendment to the Development and Master Services Agreement CI
14/11/24 Genenta Science S.p.A. Enters into Letter of Intent with AGC Biologics S.p.A CI
01/02/23 Genenta Science S.p.A. and AGC Biologics S.p.A. Enter into A Development and Manufacturing Services Agreement CI
12/12/22 AGC Biologics and W.L. Gore & Associates Collaborate on New Protein A-Based Purification Technology and Contract Manufacturing Services for Antibody Therapies CI
16/08/22 RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies CI
07/06/21 AGC Biologics Partners with BioNTech SE to Further Supply Plasmid DNA Starting Material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility CI
12/10/20 MolMed Announces Transition of Luca Alberici from the Role of Chief Business Officer CI
03/08/20 MolMed S.p.A.(BIT:MLM) dropped from S&P Global BMI Index CI
23/07/20 AGC Inc. completed the acquisition of 93.2% in MolMed S.p.A. from Finanziaria d'investimento Fininvest S.p.A. and others for approximately €220 million. CI
Manager TitleAgeSince
Chief Executive Officer - 31/10/2024
Chief Tech/Sci/R&D Officer - 31/05/2019
Human Resources Officer - 31/12/2022
Director TitleAgeSince
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 282M
-4.83%+2.88%+55.87%+69.12% 69.4B
+0.02%+1.42%+12.77%+75.21% 57.24B
-1.34%+3.53%+23.22%+101.58% 57.62B
+2.62%-1.17%+29.37%+37.84% 43.65B
+5.09%+9.53%+26.62%+121.44% 44.03B
+8.24%+1.06%+224.03%+767.69% 38.08B
-1.86%+11.46%+26.67%+61.40% 36.31B
-2.97%-6.89%+91.79%+74.60% 32.61B
-2.18%+5.68%+36.21%-0.69% 25.47B
Average +0.28%+2.24%+58.51%+145.36% 44.93B
Weighted average by Cap. +0.05%+2.44%+53.94%+138.05%
Logo MolMed S.p.A.
Molecular Medicine SpA (MolMed) is an Italy-based company engaged in the medical biotechnology sector. The Company is active in the research, development and clinical validation of therapies for the treatment of cancer. The Company's activities include identification and development of bio-pharmaceuticals reducing the tumor mass and slowing down its growth, as well as the development of selective therapies to eliminate residual tumor tissue. MolMed's pipeline comprises two main investigational anticancer therapies: TK, which is a cell-based therapy for the treatment of leukemia, and NGR-hTNF, which is a biological drug targeting tumor blood vessels for the treatment of solid tumors. MolMed develops, conducts and validates custom studies, creating testing procedures and addressing the test specifications required for cell-based therapies. It is also active in the production of cell-based medicinal products used in clinical trials and drug development of cell-based therapies.
Employees
-